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AbstrACt
Objectives To examine risk perception, beliefs about 
migraine medications and medical adherence among 
pregnant and breastfeeding women with migraine.
Design and setting Cross-sectional study conducted in 
Norway from October 2013 to February 2014. Data were 
collected via an anonymous, electronic questionnaire.
Participants Women with migraine, either pregnant or 
having delivered within the previous 18 months.
Main outcomes Women’s perception of teratogenic risk 
(numeric rating scale 0–10) was obtained for 14 different 
drugs/substances, including medications commonly used 
in the acute treatment of migraine. Women’s perspectives 
on migraine drug therapy were assessed by 10 statements 
from the Beliefs about Medicines Questionnaire (BMQ-
Specific) and six pregnancy/breastfeeding-specific 
statements. Adherence to migraine treatment during 
pregnancy and breastfeeding period was assessed by 
maternal self-report.
results The study population included 401 women with 
migraine, of which 140 were pregnant and 261 were 
new mothers. More than 70% of the women reported 
use of migraine medications during pregnancy. Still, 
the majority severely overestimated the risk associated 
with migraine medications and were concerned about 
using medications to manage their migraine during 
pregnancy and breastfeeding. Almost 9 out of 10 women 
had at some point deliberately avoided using migraine 
medications during their pregnancy. Women reporting use 
of migraine medications, however, were more positive 
and overestimated to a lesser extent the risks of using 
such medications in pregnancy compared with their 
counterparts.
Conclusions Women with migraine severely 
overestimated the risk associated with migraine 
pharmacotherapy in pregnancy. The majority of women 
were concerned about use of migraine medications during 
pregnancy and breastfeeding and reported non-adherence 
to needed treatment. More attention should be focused 
on women’s beliefs and concerns regarding migraine 
pharmacotherapy during pregnancy and breastfeeding 
in order to improve management of disease, reduce 
unfounded concerns and enhance adherence to needed 
treatment.
IntrODuCtIOn 
Migraine affects approximately 20%–25% 
of women of childbearing age.1 Optimal 
management of symptoms is a goal in all 
stages of life, including pregnancy and breast-
feeding period. The majority of women with 
pre-existing migraine experience an improve-
ment, or even complete remission, of symp-
toms throughout pregnancy.2–4 For women 
with mild symptoms, non-pharmacological 
approaches may be sufficient, but in patients 
with more severe migraine, medical treat-
ment is still often required. Previous studies 
have shown that more than 70% of women 
with migraine in pregnancy report use of 
migraine medications.5 6
Commonly used medications to treat 
acute migraine attacks include triptans 
and non-opioid analgesics such as parac-
etamol and non-steroidal anti-inflammatory 
drugs (NSAIDs). Paracetamol is considered 
the safest option during pregnancy and 
strengths and limitations of this study
 ► First study to explore risk perception, beliefs about 
migraine medications and medical adherence in 
pregnant and breastfeeding women with migraine.
 ► Women’s own perspectives on management of 
migraine during pregnancy and breastfeeding may 
help healthcare professionals better understand the 
impact of the disease and how to provide optimal 
healthcare to this patient group.
 ► Studies using electronic questionnaires carry a 
potential risk of selection  bias towards the more 
literate population. However, using the internet for 
recruitment and data collection enabled us to reach 
women with migraine nationwide.
 ► The validity of self-reported data relies on the accu-
racy of respondents’ recall.
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breastfeeding and therefore recommended as the drug 
of first choice for treatment of acute pain.7 8 Nevertheless, 
many women may need alternative treatment options to 
manage their migraine sufficiently. As experience with use 
in pregnancy and during breastfeeding is still limited for 
many migraine medications, it is often difficult to decide 
whether maternal benefit of medical treatment outweighs 
the potential risk to the fetus or breastfed infant.
In order to provide optimal migraine management 
and counselling to pregnant and breastfeeding women, 
knowledge about their perceptions and beliefs about 
migraine medications is necessary. Women’s beliefs will 
likely influence their decision for whether to use a needed 
medication or not, as indicated by previous studies on 
medication use among pregnant women.9–12 Overall, only 
a few drugs are proven to have teratogenic effects, and 
less than 2% of all birth defects are thought to arise from 
drug exposure.13 However, several studies have demon-
strated that pregnant women,14–19 and also physicians and 
other healthcare professionals,18–21 tend to overestimate 
the risks associated with maternal medication use during 
pregnancy. This misperception may have negative conse-
quences, resulting in suboptimal treatment, discontinua-
tion of needed therapy or even impact womens’ decision 
to terminate a wanted pregnancy.22 Evidence-based coun-
selling of pregnant women on the risks and benefit of 
medical treatment has proved effective in lowering unre-
alistically high risk perception.17 22–24
Little attention has been focused on migraine manage-
ment during pregnancy and breastfeeding from the 
patients’ perspective. The purpose of this study was to 
explore risk perception, beliefs about migraine medica-
tions and adherence to needed treatment among preg-
nant and breastfeeding women with migraine.
MethODs
study design, study population and data collection
This study is based on data from a cross-sectional study 
conducted in Norway. Women with migraine, either preg-
nant at any gestational week or having delivered within 
the previous 18 months, were eligible to participate. 
All data were self-reported and collected via an anony-
mous, electronic questionnaire, accessible online from 
1 October 2013 to 1 February 2014. A translated version 
of the complete questionnaire is presented in a previous 
publication.25 Participants were recruited through adver-
tisements on selected national websites and/or social 
networks primarily directed at pregnant women and new 
mothers. The advertisements contained a link to the 
questionnaire and further information about the study. 
Information about the selected websites and the recruit-
ment procedure has been described in detail elsewhere.25 
Women who participated were representative of the 
general birthing population in Norway with respect to 
geographical living area.25
This paper presents the results covering risk percep-
tion, perceived needs and concerns about migraine 
medications during pregnancy and breastfeeding, and 
self-reported medical adherence during this period.
Migraine characteristics and use of migraine medication 
during and after pregnancy
All participants had to provide detailed information about 
migraine characteristics including years since onset, type 
(aura/non-aura), trigger factors, attack frequency and 
severity of migraine during and after pregnancy. They 
were asked to report any migraine medication they had 
used during pregnancy and the breastfeeding period. To 
enhance recall, the women were presented with a list of 
16 commonly used acute migraine medication including 
analgesics (paracetamol; combinations of paracetamol 
with codeine and caffeine, respectively; NSAIDs: 
ibuprofen, naproxen, diclofenac and tolfenamic acid; 
and phenazone-caffeine); migraine-specific medications 
(triptans and ergotamine); and antiemetics (metoclopr-
amide). Generic names of the drugs were given in the 
questionnaire together with their most common trade 
names. Use of other medications not covered by the list 
and use of preventive treatment were reported as free-
text entry.
risk perception and beliefs about migraine medication
Baseline perception of teratogenic risk was assessed by 
asking the women the following question: ‘Among 100 
healthy pregnant women, how many do you think will 
give birth to a child with a severe birth defect?’. The 
answers were provided as free-text entry. The prevalence 
of birth defects among all pregnancies is estimated to be 
3%–4%26; hence this was defined as the ‘true’ baseline 
risk. Subsequently, the women were presented a list of 
14 drugs and other substances including (1) analgesics 
and other medications commonly used in acute treat-
ment of migraine (paracetamol, ibuprofen [in third 
trimester], triptans and metoclopramide); (2) herbal 
medicines (ie, feverfew); (3) alcohol (in first trimester) 
and tobacco (smoking); and (4) thalidomide. They were 
asked to assign risk perception scores ranging from 0 (not 
harmful) to 10 (very harmful) according to their own 
perceived risk for the fetus in case of maternal use during 
pregnancy. In case the substance was unfamiliar to them, 
they were given the option to answer ‘Do not know’.
beliefs about migraine medication
Beliefs about migraine medication were examined by using 
the Beliefs about Medicines Questionnaire (BMQ-Spe-
cific).27 This is a validated instrument to assess patients’ 
personal views about their medicines. For our study, the 
wording of the questions was specific for migraine medi-
cations. The BMQ-Specific comprises five items assessing 
beliefs about the necessity of medication to maintain or 
improve current and future health (Specific-Necessity) 
and five items assessing concerns about prescribed medi-
cation and potential negative effects (Specific-Concerns). 
For each statement, respondents marked their level of 
agreement on a 5-point Likert scale ranging from 1 to 
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5 (1=strongly disagree, 2=disagree, 3=uncertain, 4=agree, 
5=strongly agree). The individual total item scores ranged 
from 5 to 25, with higher scores indicating stronger beliefs 
in necessity or concerns, respectively. We also calculated 
the Necessity-Concerns differential, that is, the difference 
between the Necessity and Concerns scores. A positive 
difference implies that patients perceive the benefits of 
medication to outweigh the risks, whereas scores with a 
negative sign indicate the converse.
Six additional statements were designed by the authors 
of this study to explore beliefs about migraine and medi-
cation use during pregnancy and breastfeeding. They 
were designed especially for this study by the author 
group. They reflect our clinical experience in counselling 
pregnant and breastfeeding women with migraine about 
medications. For each statement, the women marked 
their level of agreement on a 5-point Likert scale ranging 
from 1 to 5 (1=strongly disagree, 2=disagree, 3=uncertain, 
4=agree, 5=strongly agree). In the analyses, responses 
were trichotomised into agree, disagree and uncertain.
Medication adherence
Respondents’ adherence to needed migraine pharmaco-
therapy during pregnancy and breastfeeding period was 
assessed by asking, ‘Have you ever, at one or several occa-
sions, deliberately refrained from taking migraine medi-
cations because you were a) pregnant; b) breastfeeding?’ 
(Yes/No), the latter question directed to mothers only. 
Respondents confirming the question(s) were asked 
which medication(s) they had avoided and their reason(s) 
for doing so.
statistical analysis
Descriptive statistics were used to calculate the overall 
median and IQR of risk perception scores for each of 
the substances. As the risk estimates were not normally 
distributed, we used the non-parametric Mann-Whitney 
U test for comparison of risk estimates between pregnant 
women and mothers, and between users and non-users 
of the specified drug/substance, respectively. Non-para-
metric statistics were also applied for the comparison of 
beliefs about medicines (BMQ-Specific) between users 
and non-users of migraine medications during pregnancy. 
P values <0.05 were considered statistically significant. All 
statistical analyses were performed using the Statistical 
Package for Social Sciences V.24.0.
results
study population
A total of 401 women with self-reported migraine 
responded to the survey. Of these, 140 (34.9%) were 
pregnant and 261 (65.1%) had delivered within the 
previous 18 months. The mean age of the participants was 
30.0 years (median 30, range 18–46 years). Sociodemo-
graphic, lifestyle and migraine-related characteristics of 
the study population are presented in table 1.
Table 1 Overview of sociodemographic, lifestyle and 
migraine characteristics of the study population (n=401)
Characteristics N (% of n)
Status of participant
  Pregnant 140 (34.9)
  Mother 261 (65.1)
Age (years)
  ≤25 85 (21.2)
  26–30 132 (32.9)
  31–35 123 (30.7)
  ≥36 61 (15.2)
Marital status
  Married/cohabiting 380 (94.8)
  Single/divorced/other 21 (5.2)
Education*
  Primary/secondary/high school 115 (28.7)
  College/university (1–4 years) 181 (45.1)
  College/university (≥5 years) 105 (26.2)
Employment
  Yes 320 (79.8)
  No† 8 (20.2)
Parity
  Primiparous‡ 207 (51.6)
  Multiparous 194 (48.4)
Smoking during pregnancy
  No 373 (93.0)
  Yes 28 (7.0)
Alcohol use during pregnancy§
  No 390 (97.3)
  Yes¶ 11 (2.7)
Migraine type
  With aura 172 (42.9)
  Without aura/other 229 (57.1)
Years since onset of migraine**
  ≤5 73 (18.2)
  6–15 178 (44.4)
  ≥16 148 (36.9)
Migraine medication use during pregnancy
  Yes 294 (73.3)
  No 107 (26.7)
Migraine medication use during 
breastfeeding period (n=261)
  Yes 171 (65.5)
  No 90 (34.5)
*Highest educational level completed.
†Including student/housewife/other.
‡No previous children at the time of pregnancy.
§Use after awareness of pregnancy.
¶None of the respondents reported use exceeding two units/
month.
**Numbers do not add up due to missing data.
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use of migraine medication
In total, 294 (73.3%) of the women reported use of 
migraine medications (both over-the-counter [OTC] 
and prescription drugs) during pregnancy. Paracetamol 
was the most commonly used agent (266/401; 66.3%), 
followed by triptans (58/401; 14.5%) (mainly sumatriptan) 
and NSAIDs (30/401; 7.5%) (mainly ibuprofen). On 
average, the women reported use of 1.1 (median 1, range 
0–7) drugs during pregnancy. Use of herbal medicines 
for the treatment of migraine was reported by 46 (11.5%) 
women. Among the new mothers, migraine pharma-
cotherapy during breastfeeding was reported by 171 
(65.5%). A total overview of the use of migraine medi-
cations during pregnancy and breastfeeding period has 
been presented in a previous publication.25 An overview 
of use of the migraine medications assessed by risk percep-
tion scores (paracetamol, ibuprofen, triptans, metoclopr-
amide and herbal medicines) in pregnancy in general 
and during the first trimester in specific is presented in 
online supplementary table 1.
risk perception
Overall, women estimated the baseline teratogenic risk, 
that is, the chance of a healthy pregnant woman giving 
birth to a child with a severe birth defect, to be low. Of the 
312 women who answered this question, 244 (78.2%) esti-
mated the risk of severe birth defects to occur in less than 
5 of 100 births, 60 (19.2%) estimated the risk to occur in 
5–10 of 100 births, whereas 8 (2.6%) women perceived 
the risk to occur in more than 10 of 100 births. A total 
of 89 (22.2%) women did not know or left the question 
blank.
The teratogenic risk estimates of the 14 different 
drugs/substances are illustrated in figure 1. The highest 
risk estimates were assigned for thalidomide, tobacco 
(smoking) and alcohol (in first trimester), respectively. 
Regarding thalidomide, only 105/401 (26.2%) women 
were familiar with this substance and reported a corre-
sponding risk estimate. However, among the women 
who did assign a risk estimate of thalidomide, more 
than 70% rated it as 10 (very harmful). Overall, there 
were no significant differences in risk estimates between 
pregnant women and new mothers, with the exception 
of paracetamol, being ranked higher among pregnant 
women compared with new mothers (median [IQR] 2.0 
[1.0–3.0] vs 1.0 [0.0–2.0], [p=0.014]) (data not shown). 
Online supplementary table 2 presents the risk estimates 
for the specified migraine medications according to 
individual use during pregnancy, with the exception of 
naratriptan, of which use was not reported by any of the 
women during pregnancy. Risk estimates of paracetamol, 
ibuprofen (in third trimester), sumatriptan, zolmitriptan, 
rizatriptan, eletriptan and metoclopramide were signifi-
cantly higher among non-users compared with users. 
Likewise, participants reporting use of alcohol and/or 
smoking during pregnancy perceived their associated 
risk to be significantly lower than did non-users (data not 
shown). Information about use of penicillins (and natu-
rally, thalidomide) during pregnancy was not obtained in 
the survey and therefore not included in the comparisons.
Figure 1 Median teratogenic risk scores with IQR for each of the 14 drugs/substances. Risk scores were assigned in a range 
from 0 (not harmful to the fetus) to 10 (very harmful to the fetus).
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Concerning feverfew, we did not ask specifically about 
use of this substance in the questionnaire; therefore, we 
compared risk perception of feverfew between non-users 
and users of herbal medicines in general. In terms of 
absolute differences, the largest differences in median 
risk estimates were found for triptans. Sumatriptan was 
perceived as relatively safer than the other triptans.
beliefs about migraine medication
Table 2 shows the responses for each of the BMQ-Spe-
cific statements for the total study population, and table 3 
compares the median and IQR of the total BMQ-Necessity 
and BMQ-Concerns scores and the Necessity-Concerns 
differential between users and non-users of migraine 
medications during pregnancy, respectively. Women who 
reported use of migraine medication during pregnancy 
had significantly higher Necessity-Concerns differential 
scores compared with non-users, indicating that they 
more strongly considered the benefits of medical treat-
ment to outweigh the risks (table 3). The women’s beliefs 
about migraine and migraine medications during preg-
nancy/breastfeeding period are presented in table 4.
Medication adherence
A total of 350/401 (87.3%) women confirmed that they 
at one or several occasions deliberately had refrained 
from taking needed migraine medications because they 
were pregnant. Among the mothers who answered the 
corresponding question concerning medication use post-
partum (n=259), 161 (62.2%) had at one or several occa-
sions decided not to take migraine medications because 
they were breastfeeding. Triptans were the medication 
group that most women reported to avoid, both in preg-
nancy (200/350, 57.1%) and during the breastfeeding 
period (95/161, 59.0%). Other migraine medications 
frequently avoided were NSAIDs and paracetamol. The 
main reasons given for not wanting to take medications 
was fear of harming the unborn child and/or breastfed 
infant, recommendations from their doctor or other 
healthcare professionals and information from other 
sources (eg, internet and family/friends) about potential 
harmful effects. Some women had previously experienced 
a negative pregnancy outcome (ie, spontaneous abortion), 
which impacted on their decision not to use medicines 
in their current pregnancy. A representative selection of 
citations from the study participants concerning migraine 
medication and adherence of therapy during pregnancy 
and breastfeeding is presented in table 5.
DIsCussIOn
To our knowledge, this is the first study to explore risk 
perception, beliefs about migraine medications and 
medical adherence in pregnant and breastfeeding women 
with migraine. The results indicate that the perceived risk 
associated with migraine pharmacotherapy in pregnancy 
is highly overestimated among women with migraine. 
Although use of migraine medication was common in our 
study population, most of the women expressed concern 
about using such medicines during pregnancy and post-
partum. Almost 9 out of 10 women had at one or several 
occasions deliberately refrained from using migraine 
medication during pregnancy despite a perceived need 
for medication. Equivalently, more than half of the 
mothers reported occasional non-adherence to needed 
treatment during the breastfeeding period.
A particular strength of this study is its focus on women’s 
own perspectives on the management of migraine during 
pregnancy and breastfeeding. We used a validated instru-
ment to measure patients’ beliefs about medicines, and 
we assessed a number of sociodemographic, health-re-
lated and medicine-related factors. Increased awareness 
of women’s concerns and informational needs may help 






















  Without my 
medicines I would 
be very ill.
42.9 34.4 22.7
  My health in the 
future will depend 
on my medicines.
35.4 32.7 31.9
  My medicines 








  I sometimes worry 
about the long 
term effects of my 
medicines.
46.9 31.9 21.2
  My medicines are 
a mystery to me.
16.2 52.9 30.9
  My medicines 
disrupt my life.
16.2 63.3 20.5
  I sometimes worry 
about becoming 
too dependent on 
my medicines.
23.9 63.6 12.5
*The BMQ-Specific is copyrighted (Professor Rob Horne).
BMQ, Beliefs about Medicines Questionnaire. 
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healthcare professionals to better understand the impact 
of the disease and how to improve healthcare to this 
patient group. There are, however, several limitations to 
this study that need to be considered when interpreting 
the results. The questionnaire was only available through 
internet websites, which did not enable us to calculate 
a conventional response rate. Moreover, studies using 
electronic questionnaires carry a potential risk of selec-
tion bias towards the more literate population. Never-
theless, recent epidemiological studies indicate adequate 
validity of internet-based recruitment methods.28 29 Also, 
the internet penetration rate, either in households or 
at work, is high among Norwegian women of reproduc-
tive age; national statistics from the year the survey was 
conducted showed that 97% of women aged 16–44 years 
reported use of internet on a daily basis.30 Additionally, 
using the internet for recruitment and data collection 
enabled us to reach women with migraine nationwide, 
including all health regions of the country. Another 
limitation of the study is the self-report of data, relying 
on the women’s accuracy of recall. Moreover, we did not 
use a validated measure of medication adherence. We did 
not differentiate between one-time or repeated avoidance 
of medications, and were thus not able to differentiate 
between low, moderate and high levels of adherence. 
Overall, our study sample is largely comparable to the 
population of other studies conducted among Norwe-
gian female migraineurs of reproductive age with respect 
to age, marital status, parity, life-style habits and level 
of education.5 6 However, consistent with most ques-
tionnaire-based studies, our study participants had, 
on average, a higher level of education compared with 
the general female population of reproductive age in 
Norway.31 Higher level of education has previously been 
associated with higher teratogenic risk perception,14 and 
our findings may therefore be an overestimation of risk 
perception in general. These factors must be taken into 
account when interpreting the results, as they may limit 
the generalisability of our findings.
Overall, the majority of the women in our study 
(>60%) correctly estimated the baseline risk of severe 
birth defects in the general population (<5%), which 
Table 3 Beliefs about medicines according to use of migraine medication during pregnancy (n=401)
Beliefs about medicines
Total study  
population
(n=401)
Use of migraine 
medication
(n=294)
No use of migraine 
medication
(n=107)
Use versus no use 
of medication




  Necessity 15 6–24 16 9–23 12 4–20 <0.001
  Concerns 14 7–21 15 9–21 13 7–19 0.016
  Necessity-Concerns 
differential
0 −6 to 6 1 −5 to 7 −1 −8 to 6 0.003
*The BMQ-Specific questionnaire comprises the BMQ-Necessity and BMQ-Concerns subscales (total score range 5–25). Higher scores 
indicate stronger beliefs in the concepts of the subscale. The Necessity-Concerns differential is the difference between the BMQ-Necessity 
and the BMQ-Concerns scores (a positive difference implies that patients perceive the benefits of medication to outweigh the risks, whereas 
scores with a negative sign indicate the converse).
The BMQ-Specific is copyrighted (Professor Rob Horne)
BMQ, Beliefs about Medicines Questionnaire. 
Table 4 Women’s beliefs about migraine and migraine medications during pregnancy and breastfeeding period (n=401)
Statements* % Agree % Disagree % Uncertain
I feared that my migraine would get worse during pregnancy (n=383). 83.0 11.5 5.5
I used less migraine medication than needed due to the fact that I was pregnant 
(n=310).
85.2 11.0 3.9
I was worried that my migraine medication might affect my unborn child (n=301). 89.7 7.0 3.3
In my experience, my doctor had sufficient knowledge of the usage of 
medications during pregnancy (n=345).
40.3 33.0 26.7
Even if I suffered a migraine attack during pregnancy, I refrained from taking any 
medication, just to be on the safe side (n=351).
82.9 13.1 4.0
I am unsure whether breastfeeding is safe while taking migraine medications 
(n=338).
71.3 14.8 13.9
*Number of women responding to each statement in parentheses. Respondents answering ‘Does not apply to me’ are treated as missing 
values.
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correlate with findings from previous studies assessing 
risk perception related to medication exposure in preg-
nancy.14 15 Not unexpectedly, thalidomide, tobacco 
(smoking) and alcohol were the substances perceived 
to be the most harmful, which is also similar to findings 
from other studies.14 15 The tragedy of thalidomide in the 
early 1960s32 led to an increased public awareness of the 
potential harmful effects associated with maternal medi-
cation use in pregnancy. Nevertheless, a surprisingly low 
proportion (only 26%) of the women in this study were 
familiar with thalidomide and rated it by risk perception 
scores, possibly indicating that the general awareness of 
thalidomide and its teratogenic potential is declining. 
This tendency has also been observed in a previous 
study.15 The potential harmful effects of smoking (risk of 
low infant birth weight and premature birth) and use of 
alcohol (risk of fetal alcohol syndrome) during pregnancy 
are well documented, and government policies advise all 
pregnant women to completely abstain from use. Notice-
ably, those participants reporting use of alcohol and/or 
smoking during pregnancy perceived their associated risk 
to be significantly lower than non-users. Of the migraine 
medications assessed by risk perception scores, women 
rated paracetamol as the safest, which is in line with 
current treatment recommendations. We were concerned 
that recent findings indicating increased risk of neurode-
velopmental effects with prolonged use of paracetamol 
during pregnancy33 34 may have affected risk percep-
tion of short-term use, such as in treatment of migraine 
attacks. The fact that women with migraine perceived the 
risk of paracetamol use to be low is reassuring.
Triptans, however, being the most commonly used 
migraine-specific agents, were overall given unrealistically 
high risk estimates. This correlates with the finding that 
triptans were the medications that most women reported 
to avoid in pregnancy. Noteworthy, sumatriptan was 
perceived as relatively safer to use during pregnancy than 
the other agents in this medication group. This percep-
tion might be influenced by current prescribing practice, 
as sumatriptan is often considered the first choice if treat-
ment with triptans is considered necessary in pregnancy, 
owing to the longest clinical experience with use in preg-
nant women. Findings from published studies on triptan 
use during pregnancy are reassuring. One large popu-
lation-based study did not observe that triptan therapy 
during pregnancy was associated with an overall increased 
risk of congenital malformations.35 Overall, reported risk 
estimates of paracetamol, ibuprofen, sumatriptan, zolmi-
triptan, rizatriptan, eletriptan and metoclopramide were 
significantly higher among non-users compared with 
users of the respective substances. This finding implies 
that perceived risk of medication use may influence 
the decision for whether to use a medication. Women 
perceiving migraine medications as more harmful may be 
more reluctant to use during pregnancy even if they expe-
rience a migraine attack that requires treatment.
Those women reporting use of migraine medication 
during pregnancy expressed more positive attitudes 
Table 5 Selected citations from the study participants concerning migraine medication and adherence of therapy during 
pregnancy and breastfeeding*
Pregnancy ‘For me, it was absolutely out of the question to take such strong medications while pregnant. But it was 
tough and I was extremely ill’.
(Mother, 35 years, refraining from use of triptans and NSAIDs during pregnancy)
‘ I was afraid it would harm by baby. My doctor discouraged me from taking any migraine medications while 
pregnant if I could manage without it, so I did. He recommended sick-leave before use of medications so I 
have been on sick-leave from week 10’.
(Pregnant woman, 32 years, refraining from use of sumatriptan, paracetamol and ibuprofen during pregnancy)
‘I didn’t want to take any risks, even if there might be no reason to be worried. I felt that my doctor had little 
knowledge about the issue’.
(Mother, 32 years, refraining from use of diclofenac during pregnancy)
‘I have had several spontaneous miscarriages, and I feared that something might happen to my baby’.
(Pregnant woman, 23 years, refraining from use of paracetamol/codeine during pregnancy)
‘ I didn’t want to expose my child for any potential drug effects. However, I didn’t understand that my physical 
health condition during an attack might have negative effects as well’.
(Pregnant woman, 29 years, refraining from use of rizatriptan during pregnancy)
Breastfeeding ‘I just assumed it would still be dangerous, as I was discouraged from using it during pregnancy’.
(Mother, 27 years, refraining from use of ibuprofen during breastfeeding)
‘I initiated breastfeeding for a week, and pumped and discarded milk for 12 hours after taking a tablet. So I 
soon discontinued breastfeeding because of this’. 
 (Mother, 22 years, discontinuing breastfeeding because of use of sumatriptan) 
*The citations constitute a representative selection of statements from study participants confirming the following question(s): ‘Have you ever, 
at one or several occasions, deliberately refrained from taking migraine medications because you were a) pregnant; b) breastfeeding?’.
NSAIDs, non-steroidal anti-inflammatory drugs.
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towards medications, and they more strongly considered 
the benefit of their medicines to outweigh the risk, as 
demonstrated by the higher BMQ Necessity-Concerns 
differential scores compared with non-users. Neverthe-
less, when the women were asked specifically about their 
concerns related to fetal drug exposure, 9 out of 10 women 
confirmed that they had worried whether their migraine 
medications might affect their unborn child (table 4). 
Overall, this was the most commonly given reason for 
not adhering to needed treatment. Many women stated 
that they would rather suffer a migraine attack untreated 
than to take any risks, however small they might be. Some 
women had previously experienced a negative pregnancy 
outcome (ie, miscarriage), which influenced their deci-
sions to abstain from medications in their current preg-
nancy. It was also evident that women had concerns about 
medicines and breastfeeding. Of the women responding 
to the statement ‘I am unsure whether breastfeeding is 
safe while taking migraine medications’, more than 70% 
agreed or strongly agreed to the statement. A few women 
even reported that they discontinued breastfeeding 
because they were taking medications and feared the 
consequences of exposing their infant to potential drug 
effects. This illustrates the need for more available and 
consistent information to pregnant and breastfeeding 
women about the safety of their medicines.
Considering the high prevalence of migraine among 
women of childbearing age and the high proportion of 
women reporting use of migraine medications during 
pregnancy and breastfeeding, more attention should 
be focused on the quality of healthcare provided to this 
patient group. Our study clearly illustrates the need for 
adequate and individually tailored counselling of women 
in how to manage their disease during pregnancy and 
breastfeeding period. Counselling should address the 
expected course of migraine throughout pregnancy and 
postpartum, provide weighted information about the 
benefit and potential risk of current medical treatment 
and consider alternative treatment options if necessary. 
Issues related to medical treatment should preferably 
be addressed before pregnancy is contemplated and 
ought to be an integrated part of maternity care visits. 
More effort should be made to actively involve women 
themselves in making decisions about medication use to 
promote adherence to needed treatment during preg-
nancy and breastfeeding. Continual assessment of disease 
activity and need for medication can be managed by 
keeping a headache diary and may aid in the communi-
cation between the patient and her healthcare provider. 
Moreover, a standardised assessment will secure early 
identification of women with special needs who may 
require closer follow-up in pregnancy. If necessary, 
one should consider referring the woman to specialist 
services (ie, neurologist). Enhanced collaboration and 
communication between midwives, general practitioners 
and community pharmacists is important, as they fulfil 
complementary roles as care givers and providers of 
information. Healthcare professionals should actively 
question women’s beliefs and concerns about their medi-
cines in order to clarify any misconceptions and possibly 
reduce unfounded concerns and promote adherence 
to prescribed therapy. In this respect, the community 
pharmacist in particular, plays an important role, being 
a highly qualified and easily accessible healthcare profes-
sional outside regular maternity check-ups. Furthermore, 
the pharmacist is often in direct contact with the woman 
when she obtains her prescription for migraine medica-
tion, or purchases OTC analgesics, and should take this 
opportunity to counsel about medication use and safety.36
Further studies are called for to evaluate the quality of 
healthcare provided to women with migraine of child-
bearing age and how their informational needs on safe 
medication use are met by doctors, pharmacists, midwives 
and other healthcare personnel involved in mater-
nity care. Suggestions for future research also include 
exploring physicians’ perception of teratogenic risk and 
their confidence in prescribing migraine medications to 
pregnant and breastfeeding women.
COnClusIOns
Many women with migraine severely overestimate the 
risk associated with migraine pharmacotherapy in preg-
nancy. A substantial proportion of the women in this 
study reported deliberate non-adherence to needed 
treatment during pregnancy and breastfeeding period in 
fear of harming their child. These findings underline the 
need for more available and consistent information to the 
public about migraine medication use during pregnancy 
and breastfeeding. Understanding women’s perceptions 
of the risk and benefit of medical treatment is essential for 
healthcare providers to promote optimal management of 
migraine during and after pregnancy, reduce unfounded 
concerns and enhance medication adherence.
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